Absci stock gets slammed by macro conditions, rising interest rates


The biotech sector is taking a beating, since such valuations tend to be based on future revenue.

Previous Women of Influence 2022: Adelina Tancioco of Surrendered Healing
Next Table of Experts: Driving Health Equity — Strategies to Foster a Healthier Community